Merck and Simcere agree joint venture

Published: 22-Jul-2011
Finance Pharmaceutical

Will initially offer drugs for cardiovascular and metabolic diseases


Merck & Co, known as MSD outside the US and Canada, is to form a joint venture with China’s Simcere Pharmaceutical Group with the aim initially of offering branded pharmaceutical products for cardiovascular and metabolic diseases in China.

No financial details were given.

In the area of cardiovascular disease, the partnership will offer a combined portfolio of drugs, which includes Merck’s Zocor (simvastatin), Cozaar (losartan) and Renitec (enalapril) and Simcere’s Xinta (levamlodipine) and Shufutan (rosuvastatin).

In the metabolic disease area, the partnership aims to maximise access in China to sitagliptin, a DPP-IV inhibitor for the treatment of type 2 diabetes.

  • Companies:
  • Merck MSD
  • Simcere Pharmaceutical Group
See more

You may also like

Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

Read more
The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Manufacturing

Merck bolsters its ADC CDMO offering with €71m Missouri manufacturing site expansion

The facility's expansion has tripled its ADC manufacturing capacity, bolstering Merck's CDMO offering for current and new clients
Research & Development

Merck acquires $700m clinical-stage bispecific antibody from Curon Biopharmaceutical

The CD3xCD19-targeting T-cell engager is currently being evaluated in Phase I/Ib/II clinical trials for a range of B-cell malignancies
Manufacturing

Merck and Daiichi Sankyo expand antibody drug conjugate commercialisation agreement

The companies will collaborate to commercialise MK-6070, a T-cell engager which has shown promise in treating patients with small cell lung cancer (SCLC)
Manufacturing

Merck expands newest biologics testing centre in Shanghai

New labs complete the second phase of the company’s €29m biologics testing centre, which was opened in 2022
Research & Development

Astex enters into agreement with Merck to identify small molecule candidates

Astex Pharmaceuticals has entered into an exclusive research collaboration with Merck to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer
Subscribe now